Despite Declining Q4 Revenues, Transgenomic to Develop Assays in 'Key Markets'

The company plans to move ahead with assay development projects for diagnosing Alzheimer's and Parkinson's disease, and for detecting KRAS mutations in colorectal, lung, and pancreatic cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.